Initiation of Immunomodulators (Thiopurines and Methotrexate)

This IBD clinical care pathway provides a guideline for health care providers when initiating immunomodulators (thiopurines and methotrexate) and its use in adults with inflammatory bowel disease.

 

DOWNLOAD THE PDF


Disclaimer: Clinical care pathways are not a substitute for the personalized judgement and care of a trained healthcare professional. 

Clare McCabe Woodrow (Alberta Health Services) and Dr. Natasha Bollegala (Women’s College Hospital & University of Toronto) led the review and update for the current version of this IBD Clinical Care Pathway.

Additional resources

For IBD Providers

For People with IBD

Please provide us with feedback! 

[Link to survey (external) OR a form (internal)]

If you have used this clinical care pathway, please take a moment to fill out this survey to provide your valuable feedback!

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest